Helen Susan Kim Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Helen Susan Kim.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Helen Susan Kim. Helen Susan Kim is President and CEO in KOSAN BIOSCIENCES INC ($KOSN) and President, CBO in KOSAN BIOSCIENCES INC ($KOSN) and Sr VP, Chief Business Officer in KOSAN BIOSCIENCES INC ($KOSN) and Director in SUNESIS PHARMACEUTICALS INC ($SNSS) and Director in ASSEMBLY BIOSCIENCES, INC. ($ASMB) and EVP, Business Development in Kite Pharma, Inc. ($KITE) and Director in Max-1 Acquisition Corp ($XCUR) and Director in Applied Molecular Transport Inc. ($AMTI).
Latest Insider Trading Transactions of Helen Susan Kim
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMTI, ASMB, XCUR, KITE, KOSN, SNSS
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20 2021 | AMTI | Applied Molecular ... | Kim Helen Susan | Director | Option Exercise | A | 47.01 | 14,343 | 674,264 | 14,343 | |
| Jul 06 2020 | AMTI | Applied Molecular ... | Kim Helen Susan | Director | Option Exercise | M | 0.02 | 800,000 | 16,000 | 0 | |
| Jul 06 2020 | AMTI | Applied Molecular ... | Kim Helen Susan | Director | Buy | M | 0.02 | 800,000 | 16,000 | 800,000 | 0 to 800 K |
| Jun 15 2020 | ASMB | ASSEMBLY BIOSCIENC ... | Kim Helen Susan | Director | Option Exercise | A | 20.47 | 10,000 | 204,700 | 10,000 | |
| Jun 08 2020 | XCUR | EXICURE, INC. | Kim Helen Susan | Director | Option Exercise | A | 2.79 | 21,693 | 60,523 | 21,693 | |
| Jun 14 2019 | XCUR | EXICURE, INC. | Kim Helen Susan | Director | Option Exercise | A | 2.78 | 21,693 | 60,307 | 21,693 | |
| May 17 2019 | ASMB | ASSEMBLY BIOSCIENC ... | Kim Helen Susan | Director | Option Exercise | A | 15.22 | 10,000 | 152,200 | 10,000 | |
| Jun 21 2018 | XCUR | EXICURE, INC. | Kim Helen Susan | Director | Option Exercise | A | 5.82 | 21,693 | 126,253 | 21,693 | |
| Jun 01 2018 | ASMB | ASSEMBLY BIOSCIENC ... | Kim Helen Susan | Director | Option Exercise | A | 42.09 | 7,500 | 315,675 | 7,500 | |
| Mar 12 2018 | ASMB | ASSEMBLY BIOSCIENC ... | Kim Helen Susan | Director | Option Exercise | A | 57.53 | 20,000 | 1,150,600 | 20,000 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 46.09 | 38,500 | 1,774,465 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 63.87 | 18,562 | 1,185,555 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 63.87 | 14,438 | 922,155 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 51.43 | 35,000 | 1,800,050 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 51.43 | 2,499 | 128,524 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 53.90 | 52,500 | 2,829,750 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 53.90 | 3,752 | 202,233 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | D | 0.00 | 17,500 | 0 | 0 | 17.5 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | U | 180.00 | 4,193 | 754,740 | 17,500 | 21.7 K to 17.5 K (-19.33 %) |
| Sep 28 2017 | XCUR | Max-1 Acquisition ... | Kim Helen Susan | Director | Option Exercise | A | 4.21 | 24,824 | 104,509 | 24,824 | |
| Sep 28 2017 | XCUR | Max-1 Acquisition ... | Kim Helen Susan | Director | Option Exercise | A | 1.03 | 24,824 | 25,569 | 24,824 | |
| Sep 28 2017 | XCUR | Max-1 Acquisition ... | Kim Helen Susan | Director | Option Exercise | A | 0.65 | 49,649 | 32,272 | 49,649 | |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 179.66 | 3,171 | 569,714 | 21,693 | 24.9 K to 21.7 K (-12.75 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 6,000 | 0 | 24,864 | 18.9 K to 24.9 K (+31.81 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 2,656 | 136,598 | 37,344 | |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 3,595 | 193,771 | 56,407 | |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 120.09 | 6,251 | 750,683 | 18,664 | 24.9 K to 18.7 K (-25.09 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 2,656 | 136,598 | 24,915 | 22.3 K to 24.9 K (+11.93 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 3,595 | 193,771 | 22,259 | 18.7 K to 22.3 K (+19.26 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 79,949 | 4,309,251 | 60,002 | |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 121.37 | 13,274 | 1,611,065 | 18,664 | 31.9 K to 18.7 K (-41.56 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 120.40 | 31,165 | 3,752,266 | 31,938 | 63.1 K to 31.9 K (-49.39 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 119.94 | 18,936 | 2,271,184 | 63,103 | 82 K to 63.1 K (-23.08 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 118.61 | 3,800 | 450,718 | 82,039 | 85.8 K to 82 K (-4.43 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 117.27 | 1,700 | 199,359 | 85,839 | 87.5 K to 85.8 K (-1.94 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 115.02 | 11,074 | 1,273,731 | 87,539 | 98.6 K to 87.5 K (-11.23 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 79,949 | 4,309,251 | 98,613 | 18.7 K to 98.6 K (+428.36 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 16,550 | 892,045 | 139,951 | |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 10,099 | 519,392 | 40,000 | |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 111.60 | 672 | 74,995 | 18,664 | 19.3 K to 18.7 K (-3.48 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 110.55 | 2,725 | 301,249 | 19,336 | 22.1 K to 19.3 K (-12.35 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 109.74 | 7,448 | 817,344 | 22,061 | 29.5 K to 22.1 K (-25.24 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 108.75 | 15,804 | 1,718,685 | 29,509 | 45.3 K to 29.5 K (-34.88 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 16,550 | 892,045 | 45,313 | 28.8 K to 45.3 K (+57.54 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 10,099 | 519,392 | 28,763 | 18.7 K to 28.8 K (+54.11 %) |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 2,400 | 123,432 | 50,099 | |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.45 | 2,400 | 173,880 | 18,664 | 21.1 K to 18.7 K (-11.39 %) |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 2,400 | 123,432 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 2,400 | 129,360 | 156,501 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 82.12 | 2,400 | 197,088 | 18,664 | 21.1 K to 18.7 K (-11.39 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 2,400 | 129,360 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 2,400 | 129,360 | 161,301 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 16,299 | 878,516 | 163,701 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 31,601 | 1,625,239 | 52,499 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 79.92 | 400 | 31,968 | 18,664 | 19.1 K to 18.7 K (-2.10 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 79.26 | 600 | 47,556 | 19,064 | 19.7 K to 19.1 K (-3.05 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 76.93 | 200 | 15,386 | 19,664 | 19.9 K to 19.7 K (-1.01 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 75.52 | 200 | 15,104 | 19,864 | 20.1 K to 19.9 K (-1.00 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 73.64 | 100 | 7,364 | 20,064 | 20.2 K to 20.1 K (-0.50 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.69 | 200 | 14,538 | 20,164 | 20.4 K to 20.2 K (-0.98 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.23 | 200 | 14,246 | 20,364 | 20.6 K to 20.4 K (-0.97 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 70.29 | 300 | 21,087 | 20,564 | 20.9 K to 20.6 K (-1.44 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 68.95 | 200 | 13,790 | 20,864 | 21.1 K to 20.9 K (-0.95 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 2,400 | 129,360 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.60 | 300 | 21,780 | 18,664 | 19 K to 18.7 K (-1.58 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.65 | 1,800 | 128,970 | 18,964 | 20.8 K to 19 K (-8.67 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.16 | 9,049 | 643,927 | 20,764 | 29.8 K to 20.8 K (-30.35 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 69.63 | 2,553 | 177,765 | 29,813 | 32.4 K to 29.8 K (-7.89 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 68.74 | 900 | 61,866 | 32,366 | 33.3 K to 32.4 K (-2.71 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 67.49 | 2,500 | 168,725 | 33,266 | 35.8 K to 33.3 K (-6.99 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 66.32 | 10,326 | 684,820 | 35,766 | 46.1 K to 35.8 K (-22.40 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 65.81 | 18,072 | 1,189,318 | 46,092 | 64.2 K to 46.1 K (-28.17 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 63.00 | 2,400 | 151,200 | 64,164 | 66.6 K to 64.2 K (-3.61 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 16,299 | 878,516 | 66,564 | 50.3 K to 66.6 K (+32.43 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 31,601 | 1,625,239 | 50,265 | 18.7 K to 50.3 K (+169.32 %) |
| Dec 27 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | A | 46.09 | 38,500 | 1,774,465 | 38,500 | |
| Dec 27 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 10,600 | 0 | 18,664 | 8.1 K to 18.7 K (+131.45 %) |
| Dec 22 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 50.86 | 936 | 47,605 | 8,064 | 9 K to 8.1 K (-10.40 %) |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 2,400 | 123,432 | 84,100 | |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 33,500 | 1,722,905 | 86,500 | |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | A | 51.43 | 120,000 | 6,171,600 | 120,000 | |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 63.01 | 2,400 | 151,229 | 9,000 | 11.4 K to 9 K (-21.05 %) |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 2,400 | 123,432 | 11,400 | 9 K to 11.4 K (+26.67 %) |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 60.08 | 33,500 | 2,012,596 | 9,000 | 42.5 K to 9 K (-78.82 %) |
| Aug 16 2016 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 33,500 | 1,722,905 | 42,500 | 9 K to 42.5 K (+372.22 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | A | 63.87 | 33,000 | 2,107,710 | 33,000 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 9,200 | 0 | 9,200 | 0 to 9.2 K |
| Jul 01 2015 | SNSS | SUNESIS PHARMACEUT ... | Kim Helen Susan | Director | Option Exercise | A | 3.01 | 40,000 | 120,400 | 40,000 | |
| Jun 30 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President and CEO | Option Exercise | D | 0.00 | 15,100 | 0 | 0 | |
| Jun 30 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President and CEO | Option Exercise | D | 1.71 | 50,000 | 85,500 | 0 | |
| Jun 30 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President and CEO | Option Exercise | D | 3.54 | 140,000 | 495,600 | 0 | |
| Jun 30 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President and CEO | Sell | J | 0.00 | 16,000 | 0 | 0 | 16 K to 0 (-100.00 %) |
| Apr 02 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President and CEO | Option Exercise | A | 1.71 | 50,000 | 85,500 | 50,000 | |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.64 | 200 | 328 | 16,000 | 15.8 K to 16 K (+1.27 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.66 | 2,400 | 3,984 | 15,800 | 13.4 K to 15.8 K (+17.91 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.69 | 2,000 | 3,380 | 13,400 | 11.4 K to 13.4 K (+17.54 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.58 | 100 | 158 | 11,400 | 11.3 K to 11.4 K (+0.88 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.63 | 1,020 | 1,663 | 11,300 | 10.3 K to 11.3 K (+9.92 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.70 | 2,641 | 4,490 | 10,280 | 7.6 K to 10.3 K (+34.57 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.68 | 1,100 | 1,848 | 7,639 | 6.5 K to 7.6 K (+16.82 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.59 | 500 | 795 | 6,539 | 6 K to 6.5 K (+8.28 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.65 | 4,900 | 8,085 | 6,039 | 1.1 K to 6 K (+430.20 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.60 | 1,039 | 1,662 | 1,139 | 100 to 1.1 K (+1,039.00 %) |
| Mar 17 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | President, CBO | Buy | P | 1.62 | 100 | 162 | 100 | 0 to 100 |
| Jan 04 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | Sr VP, Chief Busin ... | Option Exercise | A | 0.00 | 15,100 | 0 | 15,100 | |
| Jan 04 2008 | KOSN | KOSAN BIOSCIENCES ... | Kim Helen Susan | Sr VP, Chief Busin ... | Option Exercise | A | 3.54 | 140,000 | 495,600 | 140,000 |
Page: 1